Currently, no known COVID-19 vaccines or preventive medication have been developed.
SINGAPORE (June 24): Shares in Singapore eDevelopment (SeD) surged as high as 79% to 10 cents following its announcement of its in-vitro success against Covid-19 with its biotechnologies.
Earlier today, SeD’s wholly-owned subsidiary Impact Biomedical said it has successfully proved in-vitro success of Equivir, an over-the-counter (OTC) medication, and 3F Biofragrance, a surface disinfectant, against Covid-19.
